您要查找的是不是:
- The median survival for the 10 patients was 19 months. 这10例患者的中位生存时间为19个月。
- The median survival time for the entire sample was 34 months. 二年及五年的存活率各为65%25及25%25。
- The median survival was 11 months, with a 3-year survival of 24%. 平均生存时间是11个月,3年生存率为24%25。
- HR, 0.68), with a prolongation of median survival by 6 weeks. 整体危险比为0.;68),且延长整体存活率时间达6周。
- Median survival in the patients with SCLC was 3months, with NSCLC was 8. 5 months. SCLC和NSCLC的中位生存期分别为3个月和8.;5个月。
- The median survival was 18.5 months with a 1, 2 and 3-year actuarial survivalrate of 50%, 29% and 25%, respectively. 经随访;平均生存时间已达18.;5个月; 1、2和3年的生存率分别达到50%25、29%25和25%25。
- Median survival time(MST)was 10 months. Median time to progression (MTTP) was 8 months. 中位生存时间(MST)为10个月,中位进展时间(MTTP)为8个月。
- The median survival of the CMFVP group with four or more positive nodes was 9.1 years... 应译为:科学家正在研制和试验由分泌细胞因子的基因工程肿瘤细胞组成的癌疫苗。
- The median survival time was 60 months for the patients after EMR,no difference in survival between operatinon group and EMR group( P =0.729 39). EMR治疗患者中位生存期 6 0个月 ;手术与EMR治疗生存时间无显著性差异 (P =0 .;72 939)。
- The median survival time(MST) of N-Control, C-Control and Dex was 10, 17 and 16 days respectively, and had no difference each other(P0.05). 三、(l)各组大鼠术后存活时间:N一Control组(n=7) MST二10天、C一Control组(n=8)MST=17天和Dex组(n=8)MST=16天,术后存活时间无明显差别;
- Results The median survival time was 53.5 months.Conclusion The prognosis is in turns related to the clinical period,patho... 结果6例的中位生存期为53.;5个月;均无瘤生存。
- The overall 1-,2-, 3-, 5- year survival rates for AMM treated by radical surgery were 55.26%, 37.76%, 31.21% and 20.34% respectively, the median survival time was 21.24 months. 根治性手术治疗AMM的1、2、3、5年生存率分别为55.;26%25、37
- The overall 1-,2-,3-,5-,10-year survival rates for AMM were 47.25%,34.17%,27.28%,17.78% and 8.89% respectively,the median survival time was 16.78 months. AMM的1年、2年、3年、5年和10年生存率分别为47.;25%25、34
- Results: (1) The median survival time(MST) of N-Control, C-Control and Dex was 9, 18 and 15 days respectively, and had no difference each other(P>0.05). 结果:(1)各组大鼠术后存活时间:N-Control组(n=7)MST=9天、C-Control组(n=8)MST=18天和Dex组(n=8)MST=15天,术后存活时间无明显差别;
- The response rate in patients with ECOG PS of 0-1 was significiantly higher than that with ECOG PS of 2. Median survival period was 11 mo and 1 year-survival rate reached 50%. ECOG PS评分0-1分病人有效率明显高于ECOG PS评分2分病人。 中位生存期为11 mo,1年生存率为50%25。
- The response rate were 37.0%(10/27)for VM26regimen and 38.7%(12/3 1)for IFO regimen,median survival time was 8.3 months for VM26regimen and 8.1 months for IFO regimen. 威猛联合方案组有效率为37.;0%25(10/27),中位生存期为8
- In group GF,5 patients(35.7%)experienced PR and MR; the median survival time was 10.1 months,CBR was 38.9%,and CA19-9 decreased by over 50% in 7 patients. GF组PR2例;MR3例;SD5例;PD4例;治疗有效率达35.;7%25;中位生存期10
- The 1-year survival vate was 30.0%(9/30) in MVP group and 39.3%(11/28) in VP group. The median survival duration was 9.6 months in MVP group and 11.5 months in VP group. 1年生存率、中位生存期在MVP和VP组分别为30·0%25(9/30)和39·3%25(11/28),9·6和11·5个月。
- Median survival duration (MSD) of IPF and PF groups was 16 (8 - 34 )months and 6.5 (4-21) months, showing also significant difference ( x 2=22.36, P<0.05) between both. 中位生存期:IPF组16个月(8-34个月);PF组为6.;5个月(4-21个月);两组间差异有显著性(X2=22
- There was also a significant effect on overall survival at 1 year (27.1% vs 13.3% in the control group; HR, 0.68), with a prolongation of median survival by 6 weeks. 一年时总体生存率也有明显区别(病例组27.;1%25,而对照组为13